deltatrials
Completed PHASE2 NCT00565448

Docetaxel in Combination With Cisplatin-5-fluorouracil for the Induction Treatment of Nasopharyngeal Carcinoma in Children and Adolescents

International Randomized Study to Evaluate the Addition of Docetaxel to the Combination of Cisplatin-5-fluorouracil (TCF) vs. Cisplatin-5-fluorouracil (CF) in the Induction Treatment of Nasopharyngeal Carcinoma (NPC) in Children and Adolescents

Sponsor: Sanofi

Conditions Carcinoma Nasopharyngeal Neoplasms
Interventions 5-fluorouracil cisplatin docetaxel
Updated 7 times since 2017 Last updated: Jul 2, 2015 Started: Nov 30, 2007 Primary completion: Mar 31, 2009 Completion: Jan 31, 2012

Listed as NCT00565448, this PHASE2 trial focuses on Carcinoma and Nasopharyngeal Neoplasms and remains completed. Sponsored by Sanofi, it has been updated 7 times since 2007, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE2

  2. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2

    First recorded

Nov 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Sanofi
Data source: Sanofi

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Abacıoğlu, Turkey (Türkiye), Ahmedabad, India, Algiers, Algeria, Ankara, Turkey (Türkiye), Bangkok, Thailand, Casablanca, Morocco, Chiang Mai, Thailand, Fuzhou, China, Istanbul, Turkey (Türkiye), Jakarta, Indonesia and 13 more location s